Cellectar Biosciences Inc (CLRB)
3.085
+0.04
(+1.48%)
USD |
NASDAQ |
May 31, 16:00
3.085
0.00 (0.00%)
After-Hours: 20:00
Cellectar Biosciences Research and Development Expense (Annual): 28.21M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 28.21M |
| December 31, 2022 | 19.22M |
| December 31, 2021 | 17.59M |
| December 31, 2020 | 10.14M |
| December 31, 2019 | 8.996M |
| December 31, 2018 | 6.835M |
| December 31, 2017 | 9.466M |
| December 31, 2016 | 4.750M |
| December 31, 2015 | 5.159M |
| December 31, 2014 | 5.964M |
| Date | Value |
|---|---|
| December 31, 2013 | 6.860M |
| December 31, 2012 | 5.123M |
| December 31, 2011 | 3.599M |
| December 31, 2010 | 2.984M |
| December 31, 2009 | 8.080M |
| December 31, 2008 | 14.53M |
| December 31, 2007 | 17.43M |
| December 31, 2006 | 6.441M |
| December 31, 2005 | 1.136M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
8.996M
Minimum
2019
28.21M
Maximum
2023
16.83M
Average
17.59M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.31M |
| Eli Lilly and Co | 9.313B |
| Actinium Pharmaceuticals Inc | 38.67M |
| Altimmune Inc | 65.80M |
| GlycoMimetics Inc | 20.07M |